Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Aptose Biosciences
Biotech
Aptose exits cancer pact after Hanmi buyout blocks development
Aptose Biosciences has scrapped a deal for a blood cancer drug candidate as part of its pending takeover by Hanmi Pharmaceutical.
Nick Paul Taylor
May 14, 2026 6:35am
The 2025 Biotech Graveyard
Oct 31, 2025 5:00am
CEO props up Aptose's finances to keep biotech from going bust
Jun 17, 2025 10:04am
Fierce Biotech launches layoff tracker—Chutes and Ladders
Apr 8, 2022 9:30am
Aptose finally ditches APTO-253 after 3-year clinical hold
Dec 20, 2021 11:45am
After nearly 3 years, FDA lifts hold on Aptose cancer drug
Jun 29, 2018 9:05am
